SynthesisTargeted oncology2024

Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.

Bi-Cheng Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.